Tawny K. Dahring

Publications by Year

Research Areas

Synthesis and biological activity, Quinazolinone synthesis and applications, HER2/EGFR in Cancer Research, Blood Coagulation and Thrombosis Mechanisms, Protein Tyrosine Phosphatases

Most-Cited Works

• → Structure−Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors(1997)142 cited
• → 2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure−Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity(1998)130 cited
• → In Vitro Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor(1997)94 cited
• → In Vitro Biological Characterization and Antiangiogenic Effects of PD 166866, a Selective Inhibitor of the FGF-1 Receptor Tyrosine Kinase(1998)89 cited
• → Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines: Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors(1998)84 cited
• → Structure−Activity Relationships for 1-Phenylbenzimidazoles as Selective ATP Site Inhibitors of the Platelet-Derived Growth Factor Receptor(1998)55 cited
• → Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-7-yl Ureas. Structure−Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity(2001)53 cited
• → The Discovery of (2R,4R)‐N‐(4‐chlorophenyl)‐N‐ (2‐fluoro‐4‐(2‐oxopyridin‐1(2H)‐yl)phenyl)‐4‐methoxypyrrolidine‐1,2‐dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor(2007)39 cited
• → PDGF Receptor Protein Tyrosine Kinase Expression in the Balloon-Injured Rat Carotid Artery(1997)34 cited
• → INHIBITION OF FGF-1 RECEPTOR TYROSINE KINASE ACTIVITY BY PD 161570, A NEW PROTEIN-TYROSINE KINASE INHIBITOR(1997)21 cited